KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash & Current Investments: 2013-2024

Historic Cash & Current Investments for Travere Therapeutics (TVTX) over the last 12 years, with Dec 2024 value amounting to $58.5 million.

  • Travere Therapeutics' Cash & Current Investments rose 204.68% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.5 million, marking a year-over-year increase of 80.17%. This contributed to the annual value of $58.5 million for FY2024, which is 0.62% up from last year.
  • Latest data reveals that Travere Therapeutics reported Cash & Current Investments of $58.5 million as of FY2024, which was up 0.62% from $58.2 million recorded in FY2023.
  • Over the past 5 years, Travere Therapeutics' Cash & Current Investments peaked at $165.8 million during FY2021, and registered a low of $58.2 million during FY2023.
  • For the 3-year period, Travere Therapeutics' Cash & Current Investments averaged around $59.5 million, with its median value being $58.5 million (2024).
  • As far as peak fluctuations go, Travere Therapeutics' Cash & Current Investments spiked by 95.53% in 2021, and later plummeted by 62.78% in 2022.
  • Over the past 5 years, Travere Therapeutics' Cash & Current Investments (Yearly) stood at $84.8 million in 2020, then spiked by 95.53% to $165.8 million in 2021, then crashed by 62.78% to $61.7 million in 2022, then decreased by 5.69% to $58.2 million in 2023, then increased by 0.62% to $58.5 million in 2024.